PCM
ESPR

Prelude Capital Management’s Esperion Therapeutics ESPR Stock Holding History

Prelude Capital Management’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-34,800
Closed -$57.4K – 1302
2024
Q3 		$57.4K Buy
+34,800
New +$70.3K ﹤0.01% 1205
2015
Q4 		– Sell
-400
Closed -$9K – 1515
2015
Q3 		$9K Buy
+400
New +$25.1K ﹤0.01% 1349

Other funds holding ESPR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Prelude Capital Management's ESPR Position: Q1 2026 in Review

Prelude Capital Management reduced its Esperion Therapeutics (ESPR) stake by 42% in Q1 2026, selling an estimated $36.1K and leaving 15,670 shares worth $42.9K. The position accounts for ﹤0.01% of the portfolio, ranked #1134.

Prelude Capital Management first reported a position in ESPR in Q2 2017 and has held it in 13 quarters since. The position peaked at $601K in Q2 2024. 205 funds tracked by Wall St. Rank hold ESPR as of Q1 2026.

  • Prelude Capital Management held 15,670 shares of Esperion Therapeutics worth $42.9K as of Q1 2026.
  • Prelude Capital Management sold 11,388 Esperion Therapeutics shares in Q1 2026, an estimated $36.1K.
  • Esperion Therapeutics made up ﹤0.01% of Prelude Capital Management's portfolio in Q1 2026, its #1134 holding.
  • Prelude Capital Management first reported a position in Esperion Therapeutics in Q2 2017 and has held it in 13 quarters since.
  • Prelude Capital Management's Esperion Therapeutics position peaked at $601K in Q2 2024.
  • 205 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.